U.S. Markets closed

Highly Rated 'Surgeon' For Biologic-Drug Makers Soars 85% In 2018

Highly Rated 'Surgeon' For Biologic-Drug Makers Soars 85% In 2018

Repligen stock is on a rampage this year as it outperforms broad medical-products stocks. The bioprocessing firm has completely transformed, its CEO says.